The AstraZeneca COVID-19 Vaccine and COVISHIELD were authorized for use in Canada on February 26, 2021, in accordance with the
Interim Order Respecting the Importation, Sale and Advertising of Drugs for Use in Relation to COVID-19. Since the time of authorization, there have been very rare reports of capillary leak syndrome (CLS) following administration of the AstraZeneca COVID-19 Vaccine. Health Canada is working with international regulators and public health authorities to review data and evidence as it becomes available on these very rare events.
Products affected
AstraZeneca COVID-19 Vaccine, COVID-19 Vaccine (ChAdOx1-S [recombinant])
5 mL solution for intramuscular injection, multiple dose vials.
Each vial contains 10 doses (each dose is 0.5 mL).
DIN: 02510847
4 mL solution for intramuscular injection, multiple dose vials.
Each vial contains 8 doses (each dose is 0.5 mL).
DIN: 02511444
Manufacturer: AstraZeneca Canada Inc.
Canadian Importer and Distributor: AstraZeneca Canada Inc.
COVISHIELD, COVID-19 Vaccine (ChAdOx1-S [recombinant])
5 mL solution for intramuscular injection, multiple dose vials.
Each vial contains 10 doses (each dose is 0.5 mL).
DIN: 02512947
Manufacturer: Serum Institute of India Pvt. Ltd.
Canadian Importer and Distributor: Verity Pharmaceuticals Inc.
Background Information
The AstraZeneca COVID-19 Vaccine and COVISHIELD are indicated for active immunization of individuals 18 years of age and older for the prevention of coronavirus disease 2019 (COVID-19).
Very rare cases of CLS, a life-threatening condition characterized by acute episodes of limb edema, hemoconcentration, hypoalbuminemia and hypotension leading to organ damage, have been reported following vaccination with AstraZeneca COVID-19 Vaccine. The European Medicines Agency reviewed 6 cases in depth, and a history of CLS was noted in 3 of these cases. One of these cases had a fatal outcome.
As of June 18, 2021, one case of CLS following vaccination with the AstraZeneca COVID-19 Vaccine has been reported in Canada.
AstraZeneca COVID-19 Vaccine and COVISHIELD are now contraindicated in individuals who have previously experienced episodes of CLS.
Health Canada continues to work with international regulators to review data and evidence as it becomes available on these very rare events.
AstraZeneca Canada Inc. and Verity Pharmaceuticals Inc. will continue to work closely with Health Canada and other regulators to monitor and ensure that the appropriate analysis and reporting of adverse events are shared with regulatory authorities around the world.